Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC - Episode 1

Risk of Recurrent Colorectal Cancer Following Definitive Therapy

September 30, 2024

Yoshiaki Nakamura, MD, PhD, discusses how the use of tissue-free circulating tumor DNA (ctDNA) analysis for detecting minimal residual disease (MRD) can enhance the prediction of recurrence in stage II to III colorectal cancer (CRC), particularly when tumor specimens are limited.

Now Viewing

EP. 1: Risk of Recurrent Colorectal Cancer Following Definitive Therapy

EP. 2: COSMOS-CRC-01: Study Design and Methodology

EP. 3: COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS

EP. 4: COSMOS-CRC-01: Sensitivity and Specificity of a Serial, Cell-Free DNA Epigenomic Platform in Detecting MRD in Real Time

EP. 5: Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC

1. Please briefly discuss the prevalence of stage II to III colon cancer recurrence after definitive therapy and the advantages of MRD detection through tissue-free ctDNA analysis, especially in cases of limitedtumor specimen availability.

a. What are some challenges to accuratelystratifying the risk of recurrence among patients with resectable stage II to III CRC?

b. Compared with tissue-based biopsy and molecular profiling, what are the short- and long-term logisticalbenefits of serial, cell-free ctDNA epigenomic assays in patients with CRC who are at risk of recurrent disease after initial definitive therapy?